HORIZON-HLTH-2022-STAYHLTH-02-01
HORIZON-HLTH-2022-STAYHLTH-02-01
Programme: Horizon Europe
13 projects · €90,063,464 total EU contribution (project-level) · 151 participating organizations · 27 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€90,063,464
Countries active
Participant organizations by country (headquarters in CORDIS).
- France (18)
- Spain (17)
- Germany (16)
- Italy (16)
- PT (12)
- BE (8)
- UK (7)
- CH (6)
- Netherlands (6)
- SE (6)
- FI (5)
- EL (4)
- US (4)
- AT (3)
- DK (3)
- IL (3)
- LV (3)
- HR (2)
- LT (2)
- PL (2)
- TR (2)
- AU (1)
- BG (1)
- EE (1)
- LU (1)
- NO (1)
- RO (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM4 projects · FR
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN3 projects · DE
- ERASMUS MC3 projects · NL
- I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO3 projects · PT
- KI3 projects · SE
- UNIVERSITAIR MEDISCH CENTRUM GRONINGEN2 projects · NL
- CSIC2 projects · ES
- EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH2 projects · DE
- IDIBAPS-CERCA2 projects · ES
- HELSINGIN YLIOPISTO2 projects · FI
- HOSPITAL CLINIC DE BARCELONA2 projects · ES
- IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE2 projects · UK
Projects
Page 1 of 2
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Imminent Disease Prediction and Prevention at the Environment Host Interface IMMEDIATE · 101095540 | HORIZON | €6,221,606 | €20,000 | Details |
Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception. PREVALUNG EU · 101095604 | HORIZON | €7,016,124 | €364,610 | Details |
Systemic Endotoxemia as the driver of chronic inflammation - Biomarkers and novel therapeutic targets for Arthritis ENDOTARGET · 101095084 | HORIZON | €6,997,820 | €0 | Details |
GLYCANS AS MASTER TRIGGERS OF HEALTH TO INTESTINAL INFLAMMATION TRANSITION GlycanTrigger · 101093997 | HORIZON | €6,771,571 | €500,000 | Details |
CArdiovascularREsolution of INflammation to promote HEALTH CARE-IN-HEALTH · 101095413 | HORIZON | €6,993,396 | €436,463 | Details |
Personalised blueprint intestinal health miGut-Health · 101095470 | HORIZON | €7,126,244 | €396,875 | Details |
PHYSICS INFORMED MACHINE LEARNING-BASED PREDICTION AND REVERSION OF IMPAIRED FASTING GLUCOSE MANAGEMENT PRAESIIDIUM · 101095672 | HORIZON | €5,808,740 | €0 | Details |
iPROLEPSIS: PSORIATIC ARTHRITIS INFLAMMATION EXPLAINED THROUGH MULTI-SOURCE DATA ANALYSIS GUIDING A NOVEL PERSONALISED DIGITAL CARE ECOSYSTEM iPROLEPSIS · 101095697 | HORIZON | €6,483,091 | €371,308 | Details |
Early Interception of Inflammatory-mediated Type 2 Diabetes INTERCEPT-T2D · 101095433 | HORIZON | €8,689,222 | €965,750 | Details |
PROTO - Advanced PeRsOnalized Therapies for Osteoarthritis – TACKLING INFLAMMATION TO IMPROVE PATIENT OUTCOMES PROTO · 101095635 | HORIZON | €7,447,875 | €486,074 | Details |